A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of V940 in Combination With Pembrolizumab and Chemotherapy as First-Line Treatment for Participants With Metastatic Squamous NSCLC (INTerpath-013)

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-520902-37-00

Enrollment

Registered

2026-03-23

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer stage IV

Brief summary

Progression-free survival (PFS), Overall survival (OS)

Detailed description

Objective response rate (ORR), Duration of response (DOR), Number of Participants With ≥1 Adverse Event (AE), Number of Participants Discontinuing From Study Therapy Due to an AE

Interventions

DRUGPACLITAXEL ALBUMIN-BOUND

DRUGPACLITAXEL

DRUGDOCETAXEL

DRUGPlacebo to V940

DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion.

DRUGmRNA-4157

DRUGCARBOPLATIN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression-free survival (PFS), Overall survival (OS)	—

Secondary

Measure	Time frame
Objective response rate (ORR), Duration of response (DOR), Number of Participants With ≥1 Adverse Event (AE), Number of Participants Discontinuing From Study Therapy Due to an AE	—

Outcome results

None listed

Source: EU CTIS · Data processed: Mar 24, 2026